Low muscle mass is prevalent among patients with cancer and is a predictor of adverse clinical outcomes. To counteract muscle loss, supplements containing βeta-hydroxy βeta-methylbutyrate, or HMB, have been proposed as a potential therapy. HMB is a metabolite of leucine that positively impacts muscle mass though promoting muscle protein synthesis and reducing muscle protein breakdown. This video summarises a systematic review that investigated the effects and safety of HMB supplementation on outcomes in patients with cancer.
The original article, “Effects of βeta-hydroxy βeta-methylbutyrate supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review,” was published in the Journal of Cachexia, Sarcopenia and Muscle.
© 2022 The Authors. Journal of Cachexia, Sarcopenia and Muscle published by John Wiley & Sons Ltd on behalf of Society on Sarcopenia, Cachexia and Wasting Disorders.
Carla M Prado, Camila E Orsso, Suzette L Pereira, Philip J Atherton, Nicolaas E P Deutz. Effects of β-hydroxy β-methylbutyrate (HMB) supplementation on muscle mass, function, and other outcomes in patients with cancer: a systematic review. J Cachexia Sarcopenia Muscle 2022 Jun;13(3):1623-1641.
